{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:41:36Z","timestamp":1760146896887,"version":"build-2065373602"},"reference-count":22,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Cancer patients receiving non-endocrine therapies are at risk of hepatitis B virus (HBV) reactivation (HBVr). Guidelines recommend HBV screening prior to treatment. The Ottawa Hospital Cancer Center implemented a screening pilot for all patients receiving FOLFOX-based regimens between January and April 2023. We assessed the pilot from a quality improvement perspective. Charts were retrospectively reviewed, and patient and disease characteristics were collected. The primary endpoint was to identify the proportion of patients who underwent HBV screening prior to treatment start. Univariate analyses assessed the association between baseline characteristics and failure to screen. Quality metrics were also reviewed. There were 32\/42 patients (76.2%) who completed screening, and 5 (11.9%) had a positive screen. The majority of eligible patients (59.5%) completed screening prior to the first treatment as intended. Four of five patients who tested positive were referred to Infectious Diseases. Of those, one received antivirals for chronic HBV. There were no treatment delays due to pending screening and no HBV reactivation. Receipt of prior systemic therapy was significantly associated with failure to screen (55 vs. 95%, OR 17.1 (95% CI 1.92\u2013153), p = 0.011). The results of this pilot highlight the importance of building HBV screening into standardized treatment plans and engaging all team members to ensure high levels of screening. Prior systemic therapy receipt was associated with failure to screen, and thus, programs should include education on the necessity of screening as recommended by medical guidelines.<\/jats:p>","DOI":"10.3390\/curroncol32010020","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T10:15:28Z","timestamp":1735640128000},"page":"20","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Implementation of a Hepatitis B Screening Program in Patients Receiving Systemic Anti-Cancer Therapy"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7431-3574","authenticated-orcid":false,"given":"Jennifer","family":"Leigh","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjeeta","family":"Mallick","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Brule","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Rambout","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Pharmacy Department, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Newton","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2992-5632","authenticated-orcid":false,"given":"Dominick","family":"Boss\u00e9","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3368-3499","authenticated-orcid":false,"given":"Curtis","family":"Cooper","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, The Ottawa Hospital, Ottawa, ON K1Y 4E9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Gotfrit","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Nguyen, M.H., Wong, G., Gane, E., Kao, J.-H., and Dusheiko, G. (2024, November 01). Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy 2020. Available online: https:\/\/journals.asm.org\/journal\/cmr.","DOI":"10.1128\/CMR.00046-19"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1155\/2001\/790915","article-title":"Epidemiology of hepatitis B in Canada","volume":"12","author":"Zhang","year":"2001","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B Reactivation Associated with Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00535-010-0331-4","article-title":"Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy","volume":"46","author":"Kusumoto","year":"2011","journal-title":"J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.6004\/jnccn.2011.0045","article-title":"Why, When, and How to Prevent Hepatitis B Virus Reactivation in Cancer Patients Undergoing Chemotherapy","volume":"9","author":"Keam","year":"2011","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/hep.22945","article-title":"Reactivation of hepatitis B","volume":"49","author":"Hoofnagle","year":"2009","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.12998\/wjcc.v9.i21.5769","article-title":"Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy","volume":"9","author":"Shih","year":"2021","journal-title":"World J. Clin. Cases"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/1756283X12450245","article-title":"Management of hepatitis B reactivation in patients receiving cancer chemotherapy","volume":"5","author":"Huang","year":"2012","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_10","unstructured":"Piescic, C., and Gallo-Hershberg, D. (2024, November 01). Hepatitis B Virus Screening and Management for Patients Receiving Systemic Treatment. Available online: https:\/\/www.cancercareontario.ca\/sites\/ccocancercare\/files\/guidelines\/full\/CCO-OH-Report-Hepatitis-B-Screening-and-Management.pdf."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Hwang, J.P., Feld, J.J., Hammond, S.P., Wang, S.H., Alston-Johnson, D.E., Cryer, D.R., Hershman, D.L., Loehrer, A.P., Sabichi, A.L., and Symington, B.E. (2024, November 01). Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update, 2020. Available online: www.asco.org\/supportive-care-guidelines.","DOI":"10.1200\/JCO.20.01757"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Hwang, J.P., Fisch, M.J., Lok, A.S.F., Zhang, H., Vierling, J.M., and Suarez-Almazor, M.E. (2013). Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-534"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10620-017-4850-1","article-title":"Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network","volume":"63","author":"Kwak","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"ref_14","first-page":"351","article-title":"Chronic Hepatitis B in Canada","volume":"12","author":"Minuk","year":"2001","journal-title":"Can. J. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3747\/co.v17i6.653","article-title":"Screening for Hepatitis B Surface Antigen before Chemotherapy: Current Practice and Opportunities for Improvement","volume":"17","author":"Lee","year":"2010","journal-title":"Curr. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1200\/JOP.2012.000597","article-title":"Hepatitis B Screening Before Chemotherapy: A Survey of Practitioners\u2019 Knowledge, Beliefs, and Screening Practices","volume":"8","author":"Lee","year":"2012","journal-title":"J. Oncol. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JOP.2010.000133","article-title":"Current Hepatitis B Screening Practices and Clinical Experience of Reactivation in Patients Undergoing Chemotherapy for Solid Tumors: A Nationwide Survey of Medical Oncologists","volume":"7","author":"Day","year":"2011","journal-title":"J. Oncol. Pract."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Ramsey, S.D., Unger, J.M., Baker, L.H., Little, R.F., Loomba, R., Hwang, J.P., Chugh, R., Konerman, M.A., Arnold, K., and Menter, A.R. (2019). Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices. JAMA Oncol., 5.","DOI":"10.1001\/jamaoncol.2018.6437"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1200\/JCO.2017.75.6387","article-title":"Models to Predict Hepatitis B Virus Infection Among Patients with Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study","volume":"36","author":"Hwang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_20","unstructured":"Andonov, A. (2013). Primary Care Management of Hepatitis B: Quick Reference, Public Health Agency of Canada."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Wang, Y. (2013). Testing for hepatitis B infection in prospective chemotherapy patients: A retrospective study. World J. Gastroenterol., 19.","DOI":"10.3748\/wjg.v19.i6.923"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/ijc.33891","article-title":"Hepatitis B virus infection and the risk of gastrointestinal cancers among Chinese population: A prospective cohort study","volume":"150","author":"Liu","year":"2022","journal-title":"Int. J. Cancer"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/1\/20\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:57:03Z","timestamp":1760115423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/1\/20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["curroncol32010020"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32010020","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2024,12,30]]}}}